Biovest International Inc.(fka BVTIQ)

[integral]

https://www.sec.gov/alj/aljorders/2017/ap-4835.pdf

[Renee]

In ALL Chapter 11 Reorganization BK's the company must have every possible opportunity to be viable going forward. When a BK Judge cancels the shares / equity it is for that purpose, to facilitate the company being viable with new shares / equity. Plus, the secured creditors want as much surety as possible so they have much of the new equity to augment their secured loans.

There are no recourses for shareholders of the cancelled equity since the U.S. BK Laws protect the company and Secured Creditors, unsecured creditors, and virtually all other approved claimants before shareholders' rights.

No Court would allow a Class Action by shareholders against the BK company after the Judge has made the Reorganization PLAN effective and simultaneously cancelled the equity. The time to have made any claim(s) was during the Reorg process, not after the effective date of Reorg.

Simply, it is too late for any actions by shareholders, and that is not merely my opinion but is stipulated in the BK Laws.

[Regatta]

Renee,do you think there will be a class action suit against BVTI for cancelling the stock?
I didn't know companies could just cancel stock.

[Renee]

Yes. BVTIQ shares were cancelled and no longer exist.

[Regatta]

Does that mean our stock is now worthless?

[Renee]

When a BK Judge cancels any series of equity / stock the stock no longer exists.

New equity belongs to Secured Creditors and any other approved claimants and stakeholders, but owners of the cancelled stock equity have no entitlements to the new equity unless otherwise stated by the BK Judge.

For BVTIQ shareholders there were no entitlements for any of the new equity.

[Regatta]

What does that mean, shares have been cancelled?

[Renee]

BVTIQ: Plan of Bankruptcy effective. Shares have been cancelled.

http://www.otcbb.com/asp/dailylist_detail.asp?d=07/09/2013&mkt_ctg=NON-OTCBB

[Regatta]

Does anyone know when this company will be out of bankruptcy?

Also what's happening with the stock, it seems to be stuck in the .03 to .05 area.

[joe_techi]

from the 10Q
http://secfilings.com/searchresultswide.aspx?link=1&filingid=9295920

Also on April 18, 2013, the Bankruptcy Court entered an order approving of the process and procedures for (i) a transaction for the sale of substantially all of our assets outside the ordinary course of business pursuant to Sections 363 and 365 of the Bankruptcy Code, and/or (ii) a transaction for the funding of an alternative plan of reorganization under the 2013 Plan, which, at a minimum, shall provide for (a) payment in full of the Prepetition and Postpetition Secured Claims (inclusive of all fees, costs, interest and other amounts owed to the Senior Secured Lenders) of the Senior Secured Lenders and (b) higher or better treatment than that proposed in the Plan for the Holders of other claims against, and equity interests in, us.

Does anyone know what "higher or better treatment" means for existing stockholders?

[simon wagstaff]

Actually more, what the heck is up?

[Caveat Emptor]

Up another 60% today.

[Caveat Emptor]

Less than 150 million shares outstanding.

[Caveat Emptor]

Up 90% today...something's brewing?

[Caveat Emptor]

What's going on here...are we coming out of bankruptcy?

[bvticmtee]

Hi all,

I work with a financial company that is a shareholder in BVTI and we are trying to gauge interest in serving on an equity committee for the bankruptcy. There is no guarantee a committee will be appointed, but we wanted to start laying the groundwork. If you might be interested in serving on the committee, please e-mail me at bvticmtee (either on Yahoo or Google mail) with your contact information and the number of shares you held on March 8, 2013.

Thanks,

Concerned Shareholder

[Renee]

BVTI filed for Bankruptcy on March 6th. Effective March 11th ticker will change to BVTIQ:

http://www.otcbb.com/asp/dailylist_detail.asp?d=03/08/2013&mkt_ctg=NON-OTCBB

[casperboo]

Why did this company even bother coming out of bankruptcy in 2010?

This is disgusting - and it's about to the end for real in a few weeks.

[Roy London]

watchin in da 2013

[surf1944]

8:24AM Biovest conducts meeting with EMA advancing process to seek EU approval for cancer vaccine (BVTI) 0.29 : Biovest International, majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (ABPI), reported milestone achievements advancing BiovaxID, including a recently conducted regulatory meeting with the European Medicines Agency (EMA) and the appointment of a key contributor to the Human Genome Project to its Scientific Advisory Board.

[joseytheoutlawwales]

Hey deadjim.

They have to repeat the most recent trial, and without conditional approval.

Still a great long play from these levels if you can afford the patience.

There will also be dilution without somebody stepping up with partnership cash, in order to fund ops and the re-trial.

[deadjim]

What happened to "The next DNDN" ?

What most people will miss on this one on just a glance is that its phase 3 immunotherapy, , ie, Dendreon.. and ABPI is a former nasdaq.

weren't these guys supposed to file an NDA and get a user fee date at some point?

[joseytheoutlawwales]

Can change quickly, true. But be cautious if only because we have no current money on hand to fund the re-trial phase III.

If it is done through shares, we take it on the chin.
If private (non-toxic) or large pharma, we're good to go.

[PennyBears]

Just a glance at the chart! Sure did pay off!

[Caveat Emptor]

What tipped you off?

[PennyBears]

Keep this on high alert! Things can change very quick now.

[joseytheoutlawwales]

My concern is not for the additional Phase III trial (although now we need to locate funding for such without horrific dilution) but why BVTI didnt receive conditional approval; ie approval pending repeat confirmatory results.

Doesn't bode well.

[surf1944]

7:23AM Biovest conducts end of Phase III Review with FDA of BiovaxID as consolidation therapy in Non-Hodgkin's Lymphoma (BVTI) 0.41 : Co identifies potential biomarker associated with significant increase in duration of cancer-free survival in vaccinated patients compared to matched controls. In the upcoming meeting with the FDA regarding the design of the confirmatory registration study, Biovest anticipates exploring the use of a specific subtype of the idiotype biomarker found in a retrospective analysis of the first Phase III clinical trial, BV301. In Biovest's analysis of the first Phase III trial, the Company identified the IgM subtype showing an 84% improvement in duration of first complete remission in patients with this biomarker who received vaccine compared to matched IgM isotype control vaccinated subjects (median of 52.9 months in vaccinated patients vs 28.7 in matched controls; adj. p=0.001). Concurrent with FDA's registration activities, Biovest will continue to advance seeking marketing approvals for BiovaxID in the European Union (EU) and Canada with those planned applications supported by evidence of clinical benefit from the three human clinical trials conducted to date in collaboration with the U.S. National Cancer Institute (NCI).

[mlkrborn]

Biovest advances process seeking European Marketing Approval for BiovaxID personalized lymphoma vaccine (BVTI) 0.41 0.00 : Co announced that the European Medicines Agency (EMA) has notified Biovest regarding the official designation of the Rapporteur and Co-Rapporteur for BiovaxID, a personalized cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma.

[rickochey]

I love this company. Numbers are not that good but I don't care.

When is the expected date of EU approval?

[mlkrborn]

Biovest eligibility to seek EU Marketing Approval for its BiovaxID Cancer Vaccine as Orphan Drug confirmed by EMA (BVTI) 0.40 +0.03 : Biovest International, majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (ABPI), announced that in response to Biovest's notice of intent to file for marketing approval previously submitted to the European Medicines Agency (EMA), the EMA has provided formal notification that Biovest is eligible to submit its planned Marketing Authorization Application (MAA) for BiovaxID under the EMA's centralized procedure as an orphan medicinal product for the treatment of follicular non-Hodgkin's lymphoma. Upon approval, BiovaxID would be the first cancer vaccine available in Europe for lymphoma patients.

[casperboo]

Does anyone else think that ASCO is going to be GREAT for BVTI?

All of the recent company PRs are pointing to amazing data, a major deal being closed, and submission of the BLA to the FDA this year, not to mention Canada and the EU.

Great things to come, and soon.

[mlkrborn]

"Biovest retains Ferghana Partners to evaluate strategic transactions (BVTI) 0.39 -0.01 : Co announced that Biovest has retained Ferghana Partners as the Company's strategic transaction advisor to evaluate/implement creative financings and partnering opportunities on a regional or global basis for BiovaxID, its late-stage personalized cancer vaccine for the treatment of non-Hodgkin's lymphoma. "

[RickKayne]

Listening to radio interview.
We are going after approval in Canada and Europe

Personalized vaccine for advanced stage follicular lymphoma. The product therapy helps prevent recurrence of the disease.

Cancer vaccines using the patients own immune system is the future of fighting cancer.

Less than two years away from potential product deployment.

[junkHustler]

Continued churning to the green side.

[junkHustler]

Lots of buying going on today.

134K Buys vs 14K Sells.

Looks like good accumulation.

[junkHustler]

"We have started the process of meeting with regulators, and, over the next few months, we expect to report on the outcomes from multiple BiovaxID clinical pre-filing meetings including with Health Canada, the EMA, individual EU national agencies, and the FDA."

Looks promising.

[junkHustler]

OneMedPlace Initiates Research Coverage on Biovest and BiovaxID® Personalized Lymphoma Vaccine

TAMPA, Fla.--(BUSINESS WIRE)--Feb. 1, 2012-- Biovest International, Inc. (OTCQB: BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: ABPI), today announced that OneMedPlace, a biotechnology-focused research and media organization engaged by Biovest, has initiated research coverage on Biovest. The new report, issued this week by Dr. Malini Chatterjee, Ph.D., discusses the anticipated regulatory pathway and market opportunity for BiovaxID®, Biovest’s personalized cancer vaccine for the treatment of certain B-cell subtypes of non-Hodgkin’s lymphoma (NHL).

Dr. Chatterjee’s report forecasts that, "Over the next several months, BVTI's market position and stock profile could change dramatically as the company prepares for key pre-filing regulatory meetings that will determine the approval pathway forward for its personalized cancer vaccine targeting the treatment of follicular lymphoma (FL), an incurable form of NHL blood cancer. Assuming positive upcoming meetings with various U.S. and international regulatory agencies including Health Canada, FDA (US) and EMA (EU), BVTI will likely apply for licensure of their active immunotherapy vaccine in 2012, seeking approval for BiovaxID® for the treatment of indolent FL."

Biovest’s Senior Vice President, Product Development & Regulatory Affairs, Dr. Carlos F. Santos, Ph.D., further elaborated on the Company’s regulatory strategy yesterday at the Phacilitate Vaccine ForumWashington 2012, stating, "We have started the process of meeting with regulators, and, over the next few months, we expect to report on the outcomes from multiple BiovaxID clinical pre-filing meetings including with Health Canada, the EMA, individual EU national agencies, and the FDA. The guidance and recommendations received at these meetings will determine the next steps in seeking approvals for BiovaxID."

The complete OneMedPlace Biovest Report can be accessed in the Media Center at Biovest's corporate website at: http://www.biovest.com/investor-relations/media-center

About Biovest International, Inc.

Biovest International, Inc. is an emerging leader in the field of active personalized immunotherapies. In collaboration with the National Cancer Institute, Biovest has developed a patient-specific, cancer vaccine, BiovaxID®, with three clinical trials completed, including a Phase III study, demonstrating evidence of safety and efficacy for the treatment of indolent follicular non-Hodgkin’s lymphoma.

Headquartered in Tampa, Florida, with its bio-manufacturing facility based in Minneapolis, Minnesota, Biovest is publicly-traded on the OTCQBâ„¢ Market with the stock-ticker symbol "BVTI", and is a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: "ABPI").

[mlkrborn]

Biovest prepares for EU Regulatory Meetings; SME status granted providing European regulatory benefits for BiovaxID personalized lymphoma vaccine (BVTI) 0.39 : Co announced that the European Medicines Agency has granted Small and Medium Sized Enterprise status to Biovest. With EMA SME status confirmed, Biovest will be provided with certain administrative and economic benefits related to the EU regulatory process for the Company's BiovaxID personalized lymphoma vaccine targeting the treatment of certain B-cell subtypes of non-Hodgkin's lymphoma.

[milehighbuck]

According to recent prs they are in the process of talking with one or more regulatory agencies ( pre BLA filing meetings with FDA, EMA, and Health Canada) and attempting to gain feedback on the next steps for submittal of the BLA. If the meetings go well we should see a BLA filing in late 1st half of 2012 or early 2nd half 2012.

[kipcher]

That is darn good question. If I remember right, in the spring I kept reading that they were shooting for the fall to have FDA approval (or at least submitted for it). That has come and gone with little info on an expected approval. The only PR that seems to be comeing out is that they are speaking at different conferences/conventions and getting some print material out in some publications. Anyone else have any info on what what state the approval process is in for BiovaxID?

kip

[Olde English 800]

please, what is FDA calender here?

[SPM555]

Potential buy signal on a volume backed break of .40.

http://onlycharts.com/2011/11/28/bvti-good-bullish-divergence-example/

[mlkrborn]

Biovest announces that FDA Grants Orphan Drug Status for personalized cancer vaccine for the treatment of Waldenstrom's Macroglobulinemia (BVTI) 0.44 +0.06 : Co announced that the FDA has granted Orphan Drug Designation to BiovaxID for the treatment of Waldenstrom's macroglobulinemia, a rare subtype of B-cell non-Hodgkin's lymphoma. This milestone advances Biovest's plans to develop and commercialize BiovaxID as an autologous active immunotherapy (personalized cancer vaccine) for the treatment of multiple subtypes of B-cell non-Hodgkin's lymphoma including follicular lymphoma and mantle cell lymphoma... Biovest is majority-owned subsidiary of Accentia Biopharmaceuticals (ABPI).

[casperboo]

Presentations are fine and the company has done many of them in 2011. What I want to hear next though, is that there has been substantial progess made with the regulatory agencies like the FDA here in the United States and similar agencies abroad.

BVTI trading in the .40s (or .30s!) is becoming quite tiresome.

[Multi-Pennys]

BVTI NEWS!!!

Biovest to Exhibit at Lymphoma Research Foundation Annual Forum
print
Biovest Intl (QB) (USOTC:BVTI)
Intraday Stock Chart

Today : Thursday 15 September 2011
Click Here for more Biovest Intl (QB) Charts.

Biovest International, Inc. (OTCQB:BVTI) today announced that the Company is scheduled to exhibit at the Lymphoma Research Foundation’s (LRF) 16th Annual North American Educational Forum on Lymphoma at the Brooklyn Marriott Hotel in New York, September 30 – October 2, 2011.

“Biovest highly supports the LRF’s mission to eradicate lymphoma and to serve those touched by this disease,” stated Samuel S. Duffey, Biovest’s President. “Our commitment to deliver a personalized idiotype vaccine (BiovaxID®) to treat lymphoma is driven by our deep concern for lymphoma patients and their families. We strongly believe that ultimately, each patient’s immune system holds the key to effectively controlling this disease, and we have accordingly designed BiovaxID as the world’s first personalized, non-immunosuppressive consolidation therapy to selectively target lymphoma. We are proud to participate again this year in the annual LRF forum, which is the most comprehensive lymphoma-specific educational conference focused on treatment options and patient support,” added Mr. Duffey.

According to Professor Dr. Volker Diehl, M.D., Ph.D., Director Emeritus for Internal Medicine at the University of Cologne, Germany, “As today is World Lymphoma Awareness Day, there are reasons to be optimistic about the future of new lymphoma treatments with the advent of promising immunotherapies such as BiovaxID with the ability to create a patient-specific vaccine capable of harnessing the power of the immune system to selectively target malignant cells. The LRF is one of the highly valued patient advocacy groups providing critical information on treatment options, patient support issues, clinical trials and the latest advances in lymphoma research to people with lymphoma and their loved ones.” Professor Dr. Diehl is a pioneer in the field of lymphoma and Founder and Chairman of the German Hodgkin Lymphoma Study Group, and was awarded the 2010 Wallace H. Coulter Award for Lifetime Achievement in Hematology by the American Society of Hematology (ASH).

To Meet with Biovest:

Event: LRF’s 16th Annual North American Ed Forum on Lymphoma

When: September 30 – October 2, 2011

Where: New York Marriott at Brooklyn Bridge (333 Adams Street, Brooklyn, NY)

Agenda: Please visit: http://www.lymphoma.org

To meet with Biovest at this LRF event, please contact Douglas Calder at 813-507-2558 or [e-mail].

About Biovest International, Inc.

Biovest International, Inc. is an emerging leader in the field of active personalized immunotherapies. In collaboration with the National Cancer Institute, Biovest has developed a patient-specific, cancer vaccine, BiovaxID®, with three clinical trials completed, including a Phase III study, demonstrating evidence of safety and efficacy for the treatment of indolent follicular non-Hodgkin’s lymphoma.

Headquartered in Tampa, Florida with its bio-manufacturing facility based in Minneapolis, Minnesota, Biovest is publicly-traded on the OTCQB™ Market with the stock-ticker symbol “BVTI”, and is a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: “ABPI”).

For further information, please visit: http://www.biovest.com

Forward-Looking Statements: Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to statements about BiovaxID®, AutovaxID™, events occurring after dates hereof, and any other statements relating to products, product candidates, product development programs, the FDA or clinical study process including the commencement, process, or completion of clinical trials or the regulatory process. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, expectations and intentions, and other statements identified by words such as "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of Biovest to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement, and Biovest undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. The product names used in this statement are for identification purposes only. All trademarks and registered trademarks are the property of their respective owners.

[TVUMAN2012]

I'm in at .254 and at .28 Holding long

[casperboo]

I added yesterday at .38. Is anyone else adding under .40?

I never expected this bargain, but am watching daily.

Enjoy.

GLTA.

[DR. EVIL]

Nice work!

Looks very professional

[lex_xxx]

Theres a group on Yahoo called "WealthyPenny" who have one of their members at the company right now. Some pics of the facility have been posted and they an appointment to see the BOD this afternoon to ask some questions.



BTVI reception area and conference area